In a large propensity-matched real-world cohort, tolvaptan exposure was associated with lower risks of VTE and mortality among patients with ADPKD, though these findings are associative and hypothesis-generating rather than causal.
Tolvaptan exposure was associated with a significantly lower risk of VTE in ADPKD patients after propensity score matching.
Tolvaptan exposure was associated with significantly lower all-cause mortality in ADPKD patients.
Tolvaptan-exposed patients had significantly lower utilisation of antithrombotic medications compared to matched controls.
Individual risks of deep vein thrombosis and pulmonary embolism were not statistically different between tolvaptan-exposed and unexposed groups.
The study population consisted of 39,180 adults with ADPKD identified from the TriNetX Global Collaborative Network from 2000 to 2025.
Subgroup analyses demonstrated generally consistent directional associations across several demographic categories, though some were limited by low event counts.
The authors caution that the retrospective observational design and possibility of residual confounding mean the findings should be interpreted as associative and hypothesis-generating rather than causal.
This research suggests that in patients with autosomal dominant polycystic kidney disease (ADPKD) — a genetic condition that causes progressive kidney damage — those who received the drug tolvaptan had lower rates of dangerous blood clots in veins (venous thromboembolism), lower rates of death, and lower use of blood-thinning medications compared to similar ADPKD patients who did not take tolvaptan. The study analyzed data from nearly 40,000 ADPKD patients drawn from a large real-world medical records database, carefully matching 1,333 tolvaptan users with 1,333 non-users on 24 different factors including age, other health conditions, and lab values, to make the comparison as fair as possible. The blood clot risk was roughly half as high in the tolvaptan group (about 2% versus 4%), and the mortality difference was even more pronounced (about 1.3% versus 3.9%). Tolvaptan is already known to slow kidney disease progression in ADPKD, but this study raises the possibility that it may also be associated with additional cardiovascular and survival benefits. Notably, when researchers looked at deep vein thrombosis and pulmonary embolism individually rather than as a combined outcome, the differences were not statistically significant, likely because these specific events were uncommon enough that the study did not have enough cases to detect a difference reliably. This research suggests a potentially important association between tolvaptan use and reduced blood clot risk in ADPKD patients, but because this was an observational study using existing medical records rather than a controlled clinical trial, it cannot prove that tolvaptan caused these better outcomes. Unmeasured factors — such as how severe each patient's kidney disease was — could still be influencing the results. The authors call for prospective clinical studies that include detailed measures of disease severity to better understand whether this association is real and, if so, why it occurs.
Chen T, Tsai S. (2026). Association Between Tolvaptan Exposure and Venous Thromboembolism Risk in ADPKD: A Real-World Propensity-Matched EHR Study.. Nephrology (Carlton, Vic.). https://doi.org/10.1111/nep.70280